Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 266,886
  • Shares Outstanding, K 30,328
  • Annual Sales, $ 23,440 K
  • Annual Income, $ -50,330 K
  • 60-Month Beta 1.59
  • Price/Sales 11.10
  • Price/Cash Flow N/A
  • Price/Book 2.25
Trade ALPN with:

Options Overview Details

View History
  • Implied Volatility 135.19% ( -16.51%)
  • Historical Volatility 48.22%
  • IV Percentile 71%
  • IV Rank 41.66%
  • IV High 257.44% on 08/01/22
  • IV Low 47.91% on 09/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 192
  • Open Int (30-Day) 182

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate 0.53
  • Low Estimate -0.54
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +81.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.63 +15.33%
on 08/02/22
9.30 -5.33%
on 07/20/22
+0.01 (+0.11%)
since 07/12/22
3-Month
6.62 +32.92%
on 05/13/22
9.89 -11.02%
on 05/27/22
+2.09 (+31.15%)
since 05/12/22
52-Week
6.00 +46.67%
on 02/22/22
14.40 -38.89%
on 12/31/21
-0.45 (-4.86%)
since 08/12/21

Most Recent Stories

More News
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided...

ALPN : 8.80 (+2.56%)
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec’s Seattle-based subsidiary, Just –...

EVO : 13.97 (+6.32%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

STVN : 18.22 (+0.66%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in...

RVMD : 25.43 (+8.21%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

3rd Resistance Point 9.54
2nd Resistance Point 9.23
1st Resistance Point 9.02
Last Price 8.80
1st Support Level 8.50
2nd Support Level 8.19
3rd Support Level 7.97

See More

52-Week High 14.40
Fibonacci 61.8% 11.19
Fibonacci 50% 10.20
Fibonacci 38.2% 9.21
Last Price 8.80
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar